These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 3228902)

  • 21. Rifampicin-induced renal toxicity during retreatment of patients with pulmonary tuberculosis.
    Rekha VV; Santha T; Jawahar MS
    J Assoc Physicians India; 2005 Sep; 53():811-3. PubMed ID: 16334628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Tuberculosis of the middle ear: a rare extrapulmonary manifestation].
    Schütte W; Berghaus A; Schütte A
    Dtsch Med Wochenschr; 1996 Dec; 121(49):1551. PubMed ID: 8998926
    [No Abstract]   [Full Text] [Related]  

  • 23. [Hemolytic anemia secondary to rifampicin in patient diagnosed of pulmonary tuberculosis reinfection].
    Díaz-Pollán B; Peña-Pedrosa JA; Nuñez-Orantos MJ; Sotres-Fernández G
    Rev Esp Quimioter; 2013 Dec; 26(4):369-70. PubMed ID: 24399351
    [No Abstract]   [Full Text] [Related]  

  • 24. Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.
    Stout JE
    Expert Opin Drug Saf; 2004 May; 3(3):187-98. PubMed ID: 15155147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A triple regimen of streptomycin, isoniazid and ethambutol or rifampicin, isoniazid and ethambutol in untreated cases of pulmonary tuberculosis. 3.
    Oka S; Sasaki M; Kobayashi T; Matsuda T
    Sci Rep Res Inst Tohoku Univ Med; 1972 Sep; 19(2):84-8. PubMed ID: 4649627
    [No Abstract]   [Full Text] [Related]  

  • 26. [Intradermal reaction to tuberculin: application, interpretation and therapeutic implications].
    Van Vooren JP
    Rev Med Brux; 2000 Feb; 21(1):A45-8. PubMed ID: 10748688
    [No Abstract]   [Full Text] [Related]  

  • 27. Another step on the path to better TB therapies.
    Vernon A; Burman W; Horsburgh CR
    Int J Tuberc Lung Dis; 2002 Jan; 6(1):1-2. PubMed ID: 11931394
    [No Abstract]   [Full Text] [Related]  

  • 28. [Estimation of the possibilities of using unified chemotherapy regimens in new cases of pulmonary tuberculosis in old-age children and adolescents].
    Gubkina MF; Ershova NG
    Probl Tuberk Bolezn Legk; 2009; (1):33-6. PubMed ID: 19256010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [An update on the antibiotic therapy of tuberculosis].
    Rossi G
    Recenti Prog Med; 1999 May; 90(5):241-3. PubMed ID: 10380549
    [No Abstract]   [Full Text] [Related]  

  • 30. Rifampicin--a mild immunosuppressive agent for psoriasis.
    Tsankov N; Grozdev I
    J Dermatolog Treat; 2011 Apr; 22(2):62-4. PubMed ID: 20653488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Place of rifampicin in the treatment of pulmonary tuberculosis].
    Despierres G; Bonnet PA; Phélip H
    J Med Lyon; 1971 Jun; 52(210):893-4 passim. PubMed ID: 5132687
    [No Abstract]   [Full Text] [Related]  

  • 32. [Comparison of therapeutic effects of rifampicin 450 mg daily and 600 mg three times weekly on the previously treated pulmonary tuberculosis patients].
    Yamamoto M; Mizutani A; Nakamura H; Hirose H; Nagata A
    Kekkaku; 1973 May; 48(5):197-202. PubMed ID: 4732658
    [No Abstract]   [Full Text] [Related]  

  • 33. [Clinical effects of rifampicin for pulmonary tuberculosis patients. 2. Results of rifampicin treatment for advanced pulmonary tuberculosis patients resistant to conventional antituberculous drugs].
    Kekkaku; 1971 Nov; 46(11):423-8. PubMed ID: 4335256
    [No Abstract]   [Full Text] [Related]  

  • 34. [Maximum therapeutic efficiency of a guternary antitubercular preparation. (Streptomycin-ethambutol-rifampicin-isoniazid)].
    Almansa de Cara S
    Rev Clin Esp; 1972 May; 125(4):353-6. PubMed ID: 5080180
    [No Abstract]   [Full Text] [Related]  

  • 35. [Comparison of inhibitory effect of rifalazil and rifampicin against Mycobacterium ulcerans infection induced in mice].
    Nakanaga K; Saito H; Ishii N; Goto M
    Kekkaku; 2004 May; 79(5):333-9. PubMed ID: 15211873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of newly diagnosed patients with infiltrative and disseminated pulmonary tuberculosis].
    Ursov IG; Krasnov VA; B1tashova VA; Kudelia OA; Volkova ZhA; Gromyko NI; Borovinskaia TA
    Probl Tuberk; 1998; (4):21-2. PubMed ID: 9771031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effectiveness of chemotherapy of intrathoracic tuberculosis in children: late follow-up data].
    Iukhimenko NV
    Probl Tuberk; 2001; (5):19-22. PubMed ID: 11588952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of intractable pulmonary tuberculosis: place of capreomycin in therapeutic programs with rifampicin and ethambutol].
    Oury M; Tuchais E; Norval C; Carbonnelle B; Leroux MF; Corre C; Parvery F
    Rev Tuberc Pneumol (Paris); 1970 Jun; 34(4):519-30. PubMed ID: 5510321
    [No Abstract]   [Full Text] [Related]  

  • 39. Factors associated with treatment success for tuberculosis patients: a single center's experience in Turkey.
    Talay F; Kumbetli S; Altin S
    Jpn J Infect Dis; 2008 Jan; 61(1):25-30. PubMed ID: 18219130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Anatomic and bacteriologic testing of rifampicin effectiveness in treatment of pulmonary tuberculosis].
    Morère P; Stain JP; Hubert J; Chauvet MC
    Rev Tuberc Pneumol (Paris); 1970; 34(3):434-8. PubMed ID: 4994941
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.